Split View: 2026년 헬스케어 & 바이오테크 트렌드 — GLP-1, 유전자 치료, AI 진단, 디지털 헬스

2026 Healthcare & Biotech Trends — GLP-1, Gene Therapy, AI Diagnostics, Digital Health

• Introduction
• 1. The GLP-1 Revolution — Beyond Obesity Treatment
  • What Are GLP-1 Receptor Agonists?
  • Key Developments in 2026
  • Next-Generation GLP-1 Pipeline
  • Convergence with Gene Therapy
• 2. Gene Therapy — From CRISPR to CAR-T
  • The First CRISPR-Cas9 Approved Therapy
  • Gene Therapy Landscape in 2026
  • Challenges
• 3. AI Medical Diagnostics — From Imaging to Pathology
  • FDA Approval Status
  • Key Application Areas
  • Evolving Regulatory Landscape
  • Limitations
• 4. Digital Health — Telemedicine, Wearables, and DTx
  • Market Size and Growth
  • The Rise of Digital Therapeutics (DTx)
  • Wearables Achieving Clinical Grade
  • Connected Care
• 5. Precision Medicine — Genomic Analysis and Personalized Treatment
  • What Is Precision Medicine?
  • Key Advances in 2026
  • Multi-Omics Integration
• 6. Neuroscience — Brain-Computer Interfaces and Neurodegeneration
  • Neuralink and BCI Technology
  • Applications for Neurodegenerative Diseases
  • Multifaceted Approaches to Alzheimer's Treatment
  • Ethical Considerations
• 7. Longevity Science — The Science of Slowing Aging
  • Senolytics
  • NAD+ Boosting
  • Telomeres and Aging
  • Metformin and the TAME Trial
  • 2026 Longevity Supplement Trends
• 8. Global Pharma Industry — M&A and the Patent Cliff
  • The Patent Cliff
  • M&A Trends
  • GLP-1 Market Competition
  • AI Transformation of Pharma
• 9. Korea's Bio Industry — K-Bio Goes Global
  • Entering the Global Top 25
  • Samsung Biologics
  • Celltrion
  • Biosimilar Third Wave
  • The BIOSECURE Act Opportunity
• 10. Personal Health Management — Preventive Medicine You Can Practice
  • The Importance of Regular Check-ups
  • Exercise: The Most Powerful Medicine
  • Sleep Hygiene
  • Nutrition and Diet
  • Mental Health Care
  • Leveraging Wearables
• Conclusion
• References

Introduction

In 2026, the healthcare and biotech industries are transforming at an unprecedented pace. GLP-1 receptor agonists are expanding beyond obesity into cardiovascular disease, Alzheimer's, and addiction treatment. CRISPR gene editing has produced the first FDA-approved therapies. AI now rivals human physicians in imaging interpretation and pathological diagnosis. Digital therapeutics (DTx) are beginning to receive insurance coverage just like prescription medications.

This article provides an in-depth look at 10 key trends in the healthcare and biotech industry as of 2026. Beyond technological advances, we examine shifts in industry structure, the regulatory landscape, and practical preventive medicine anyone can practice.

1. The GLP-1 Revolution — Beyond Obesity Treatment

What Are GLP-1 Receptor Agonists?

GLP-1 (Glucagon-Like Peptide-1) is an incretin hormone secreted by the small intestine that promotes insulin secretion, suppresses appetite, and slows gastric motility. Drugs such as semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) were originally developed for type 2 diabetes, but their powerful weight-loss effects have disrupted the obesity treatment landscape.

Key Developments in 2026

Expanded Cardiovascular Indications: In 2024, the FDA approved semaglutide (Wegovy) for cardiovascular risk reduction in overweight and obese adults. The SELECT trial demonstrated a roughly 20% reduction in major adverse cardiovascular events (MACE), making it the first weight-loss drug to receive a dedicated cardiovascular indication. In September 2025, it also received EU approval as the first stroke management therapy.

Alzheimer's Trials: Two global Phase 3 trials — EVOKE and EVOKE+ — are underway. Patients with early cognitive impairment who received semaglutide for 12 months showed approximately 18% lower plasma levels of phosphorylated tau-217 (p-tau217), a recognized biomarker for Alzheimer's progression, compared to placebo. The possibility of the first GLP-1 Alzheimer's approval by late 2026 has been raised.

Potential for Addiction Treatment: While no FDA approval exists yet, the National Institute on Alcohol Abuse and Alcoholism (NIAAA) is conducting Phase 2 trials of semaglutide for alcohol use disorder. Off-label prescribing is increasing, though insurance coverage remains limited.

MASH Approval: Wegovy was recently approved for treating metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis.

Next-Generation GLP-1 Pipeline

The emergence of oral formulations is particularly noteworthy, as they can significantly improve accessibility for patients who resist injections.

Convergence with Gene Therapy

A gene therapy approach that programs the body to produce more GLP-1 hormone naturally for years with a single infusion is also being explored. If successful, it would represent a transformative paradigm — achieving long-term effects from a single treatment instead of weekly injections or daily pills.

2. Gene Therapy — From CRISPR to CAR-T

The First CRISPR-Cas9 Approved Therapy

In December 2023, the FDA approved the first CRISPR-based gene therapy, Casgevy (exa-cel), marking a milestone in medical history. It is approved for treating sickle cell disease in patients aged 12 and older.

How It Works: Hematopoietic stem cells are harvested from the patient, then CRISPR/Cas9 is used to cut specific DNA sites to increase fetal hemoglobin (HbF) production. The modified cells are transplanted back, engraft in the bone marrow, and prevent red blood cells from sickling.

Lyfgenia, approved the same day, uses a lentiviral vector approach for the same indication.

Gene Therapy Landscape in 2026

Market Growth: Casgevy recorded over 100 million dollars in total revenue in 2025, with significant growth expected in 2026.

Expanding Applications: Clinical use of CRISPR, genetic sequencing, and multi-omics data integration is enabling highly customized therapies and diagnostics, particularly in oncology and rare diseases.

CAR-T Cell Therapy: Chimeric antigen receptor T-cell (CAR-T) therapy continues to show breakthrough results in blood cancers (leukemia, lymphoma), with active research into expanding applications to solid tumors.

Challenges

Gene therapy is revolutionary but faces significant hurdles:

• High Cost: A single Casgevy treatment costs approximately 2.2 million dollars
• Complex Manufacturing: Patient-specific production makes mass manufacturing difficult
• Long-Term Safety: Long-term monitoring for off-target effects of gene editing is required
• Access Disparities: Infrastructure concentrated in developed nations limits access in developing countries

3. AI Medical Diagnostics — From Imaging to Pathology

FDA Approval Status

The FDA has authorized 1,356 AI-enabled medical devices since it began tracking, with 1,039 (77%) in radiology. In 2023 alone, 221 were approved, and 2024 added another 125 (74.4% of total approvals).

Key Application Areas

Radiology: AI assists in chest X-ray, CT, and MRI interpretation — detecting lung nodules, identifying early hemorrhages, and screening for breast cancer. It enhances diagnostic accuracy and processing speed.

Pathology: AI algorithms analyze tissue samples and laboratory results to help pathologists identify abnormalities. However, no comprehensive program can accurately detect all pathological features; the field currently relies on a suite of specialized AI tools.

Disease Subtype Classification: AI-enabled diagnostics identify disease subtypes to ensure patients receive the most effective therapies.

Evolving Regulatory Landscape

EU AI Act: Effective January 2026, the EU AI Act explicitly classifies medical AI as high-risk, requiring rigorous evaluation of accuracy, explainability, and bias.

FDA Predetermined Change Control Plans (PCCP): The FDA has launched pilot programs allowing manufacturers to update AI model weights without full re-submission — a significant regulatory innovation that could accelerate continuous AI improvement.

Faster Approvals: As of 2025, the median clearance time for AI/ML devices was 142 days, with 25% cleared in under 90 days.

Limitations

Human oversight remains essential. Even with AI assistance, the final diagnostic responsibility lies with the radiologist. Challenges including training data bias, poor performance on rare diseases, and the "black box" problem remain.

4. Digital Health — Telemedicine, Wearables, and DTx

Market Size and Growth

The global telemedicine market reached approximately 124 billion dollars in 2026, while the U.S. wearable health tech market grew to 30 billion dollars. The digital therapeutics (DTx) market surged from 3 billion dollars in 2024 to approximately 5 billion dollars in 2025.

The Rise of Digital Therapeutics (DTx)

Digital therapeutics are evidence-based software solutions that prevent, manage, or treat diseases. They are now being prescribed like medications for mental health, pain, and insomnia, with expanded insurance coverage through new CMS billing codes for behavioral health DTx.

Key DTx examples include:

• Insomnia: CBT-I (Cognitive Behavioral Therapy for Insomnia) apps prescribed as alternatives to sleeping pills
• Type 2 Diabetes: Lifestyle management apps that assist blood glucose control
• Substance Use Disorders: Cognitive behavioral therapy programs
• ADHD: FDA-approved game-based digital treatments

Wearables Achieving Clinical Grade

After the FDA issued late-2025 guidance recognizing real-world evidence (RWE) from wearables, consumer wearable data is being elevated to clinical grade. Moving beyond simple step counting, wearables now generate multi-signal, longitudinal datasets that support remote monitoring and clinical decision-making.

Connected Care

The key theme for digital health in 2026 is integration. Smart connected care — combining AI diagnostics, digital therapeutics, wearables, and data interoperability — is becoming mainstream. Remote monitoring and digital biomarkers provide real-time health insights, and adherence solutions for complex therapy regimens are expanding.

5. Precision Medicine — Genomic Analysis and Personalized Treatment

What Is Precision Medicine?

Precision medicine tailors treatments to individual patients based on their genetic, environmental, and lifestyle characteristics. Unlike the one-size-fits-all standard of care, it analyzes each person's genomic information to select the most effective drugs and dosages.

Key Advances in 2026

Declining Genomic Sequencing Costs: Whole genome sequencing (WGS) costs have fallen below 100 dollars, making clinical genomic testing widespread.

Pharmacogenomics: Analyzing genetic variations in drug metabolism enables personalized prescriptions that minimize side effects and maximize efficacy. Research published in April 2026 indicates that GLP-1 drug effectiveness may vary with genetic background.

Liquid Biopsy: Analyzing circulating tumor DNA (ctDNA) in blood enables early cancer detection and treatment response monitoring.

Personalized Cancer Therapy: Tumor genetic profiling guides targeted therapy selection, and personalized neoantigen vaccines are under active development.

Multi-Omics Integration

The integration of genomics, transcriptomics, proteomics, and metabolomics data is expanding. This multi-omics approach enables multifaceted understanding of disease mechanisms and more sophisticated diagnostic and treatment strategies.

6. Neuroscience — Brain-Computer Interfaces and Neurodegeneration

Neuralink and BCI Technology

Elon Musk's Neuralink has announced plans to establish mass production of BCI (Brain-Computer Interface) implants by 2026 and to nearly fully automate the implantation procedure. The surgical approach involves passing electrode threads through the dura mater without removing it.

Applications for Neurodegenerative Diseases

Longitudinal tracking of neural activity through BCI could offer unprecedented insights into neurodegenerative diseases such as Alzheimer's, Huntington's, and ALS. It enables early detection and targeted interventions, with the potential to improve patient outcomes and quality of life.

Multifaceted Approaches to Alzheimer's Treatment

Alzheimer's research is advancing on multiple fronts:

• Anti-Amyloid Antibodies: Lecanemab (Leqembi) and donanemab show effects in slowing cognitive decline in early Alzheimer's patients
• GLP-1 Drugs: The EVOKE/EVOKE+ trials mentioned above
• Tau-Targeted Therapies: Treatments targeting tau protein, another key Alzheimer's pathology
• Digital Cognitive Training: AI-based cognitive rehabilitation programs

Ethical Considerations

BCI technology raises serious ethical questions alongside its medical innovations. Brain data privacy, equity in cognitive enhancement, and device hacking risks are being actively discussed in academia and regulatory bodies.

7. Longevity Science — The Science of Slowing Aging

Senolytics

Senolytic drugs that selectively eliminate senescent (aging) cells are gaining attention. Natural compound-based senolytics such as fisetin and spermidine are under study, and the dasatinib-plus-quercetin (D+Q) combination is in clinical trials.

NAD+ Boosting

NAD+ (Nicotinamide Adenine Dinucleotide) is a critical coenzyme for energy metabolism, DNA repair, and cell signaling that declines with age. Supplementation with NAD+ precursors — NMN (Nicotinamide Mononucleotide) and NR (Nicotinamide Riboside) — is a core strategy in longevity science.

A notable 2026 finding suggests that combining senolytic therapy with NAD+ boosting may enhance efficacy and safety beyond either approach alone, with potential additive or synergistic benefits for aging, healthspan, and longevity.

Telomeres and Aging

Telomeres are protective structures at chromosome ends that shorten with each cell division. Research into telomerase activation for telomere extension is ongoing, and telomere length is being used as a biological age indicator.

Metformin and the TAME Trial

The TAME (Targeting Aging with Metformin) clinical trial is testing whether the diabetes drug metformin has anti-aging effects. This trial is significant as it could set a precedent for the FDA recognizing aging itself as a treatable condition.

2026 Longevity Supplement Trends

The main categories of longevity-related supplements include:

• NAD+ Precursors: NMN, NR
• Polyphenols: Resveratrol, curcumin
• Senolytic Compounds: Fisetin, spermidine
• Omega-3 Fatty Acids: EPA, DHA
• Vitamin D: Immune function and bone health

However, large-scale clinical evidence for supplement efficacy remains limited, so consultation with healthcare professionals is recommended.

8. Global Pharma Industry — M&A and the Patent Cliff

The Patent Cliff

The global pharmaceutical industry faces the structural challenge of blockbuster drug patent expirations. Between 2028 and 2033, approximately 85 billion dollars worth of cancer and biologic drugs will lose patent protection. Daratumumab (Darzalex) patents begin expiring in 2026, with late-stage biosimilar development already underway.

M&A Trends

In anticipation of the patent cliff, major pharma companies are actively acquiring innovative pipelines. Biotech companies in obesity/metabolic disease, immunology, and oncology are primary acquisition targets. Six major obesity-related deals in 2025 alone are shaping the industry landscape for 2026 and beyond.

GLP-1 Market Competition

The GLP-1 market is transitioning from a Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide) duopoly to a multi-player landscape, with later entrants pursuing differentiated mechanisms and formulations. Oral formulations, long-acting variants, and gene therapy approaches are forming new competitive axes.

AI Transformation of Pharma

Generative AI and machine learning are being actively applied to drug discovery, clinical trial design, and precision medicine. AI is increasingly shortening candidate molecule identification from years to months and improving clinical trial efficiency.

9. Korea's Bio Industry — K-Bio Goes Global

Entering the Global Top 25

Samsung Biologics and Celltrion have been named among the global top 25 biotech companies. Both were invited to present at the main stage of the JP Morgan Healthcare Conference (JPM 2026) in January 2026, confirming their global stature.

Samsung Biologics

Samsung Biologics has grown into the world's largest biopharmaceutical CDMO by production capacity. At JPM 2026, it announced a three-pillar expansion strategy, declaring its intent to join the top tier of global CDMOs.

U.S. Market Expansion: It is acquiring Rockville assets from GSK for 280 million dollars (closing expected Q1 2026), strengthening its U.S. manufacturing capabilities.

Celltrion

Celltrion, Korea's leading biosimilar company, presented "innovative drugs" and "the U.S. market" as key themes at JPM 2026.

Massive Investment: In March 2026, Celltrion committed 805 million dollars to expand its Incheon facility and acquired Eli Lilly's Branchburg, NJ plant for approximately 330 million dollars, bringing total capacity to 570,000 liters per year.

Biosimilar Third Wave

The global biosimilar market is entering its third wave of expansion. As approximately 85 billion dollars worth of blockbuster cancer and biologic drug patents expire between 2028 and 2033, massive opportunities are opening for Korean biosimilar companies.

The BIOSECURE Act Opportunity

As the U.S. BIOSECURE Act strengthens restrictions on Chinese biotech companies, Korean firms are emerging as alternative suppliers. Samsung Biologics, Celltrion, and Alteogen are drawing attention as beneficiaries.

10. Personal Health Management — Preventive Medicine You Can Practice

The Importance of Regular Check-ups

No matter how advanced medicine becomes, nothing is more effective than early detection. Getting regular check-ups appropriate to your age and risk factors is the most fundamental and important preventive measure.

Age-Appropriate Screening Guide:

20s-30s: Basic blood tests, blood pressure, BMI, STI screening
30s-40s: + Lipid panel, thyroid function, liver function tests
40s-50s: + Colonoscopy (from 45), mammogram (women), prostate exam (men)
50s+:    + Bone density scan, low-dose CT (if smoking history), early dementia screening

Exercise: The Most Powerful Medicine

Regular exercise reduces the risk of cardiovascular disease, type 2 diabetes, cancer, dementia, and virtually all chronic diseases. WHO recommendations include:

• Aerobic Exercise: 150-300 minutes moderate or 75-150 minutes vigorous per week
• Strength Training: At least 2 sessions per week covering major muscle groups
• Flexibility/Balance: 2-3 sessions per week

Sleep Hygiene

Sleep directly affects immune function, cognitive performance, and metabolic health. The essentials are securing 7-9 hours of sleep, maintaining consistent sleep-wake times, and reducing blue light exposure before bed.

Nutrition and Diet

• Mediterranean Diet: Effective for cardiovascular and cognitive decline prevention
• Limit Processed Foods: Ultra-processed foods increase obesity, diabetes, and cancer risk
• Adequate Protein: 1.2-1.6g per kg of body weight to prevent sarcopenia
• Hydration: 1.5-2 liters of water daily

Mental Health Care

Stress management, social connections, and mindfulness meditation play critical roles in both mental and physical health. Digital therapeutics (DTx) offering cognitive behavioral therapy are an accessible option.

Leveraging Wearables

Smartwatches and fitness trackers can monitor heart rate, sleep patterns, and activity levels, enabling early detection of anomalies. In 2026, with wearable data gaining greater clinical recognition, sharing this data with healthcare providers is a smart strategy.

Conclusion

The 2026 healthcare and biotech industry is in an era of convergence — multiple revolutions happening simultaneously. GLP-1 drugs are expanding from obesity into neuroscience, CRISPR is fundamentally curing genetic diseases, AI is transforming diagnostic paradigms, and digital technology is revolutionizing healthcare accessibility.

Yet technology alone does not solve everything. Healthy lifestyle habits — regular exercise, balanced diet, adequate sleep, and stress management — remain the most effective and cost-efficient preventive medicine.

Let us look forward to medical advances while starting with the health management we can do today. Maintaining our health until future treatments can save us — that is the true longevity strategy.

References

• IQVIA, "Outlook for Obesity in 2026: From Consolidation to Acceleration"
• FDA, "Artificial Intelligence-Enabled Medical Devices"
• Genetic Literacy Project, "Gene therapy could revolutionize the GLP-1 industry"
• Alzheimer's Association, "GLP-1s and Alzheimer's: What You Need to Know"
• STAT News, "What counts as an AI breakthrough device for the FDA?"
• GEN Edge, "Seven Biopharma Trends to Watch in 2026"
• Galen Growth, "Digital Health 2026: From Hype to Hardwiring"
• KBR, "Samsung Biologics and Celltrion included in top 25 global biotech firms"
• StartUs Insights, "Top 10 Digital Health Trends in 2026"